Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer

NCT07199764 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Ductal Adenocarcinoma

Interventions

DRUG: Odetiglucan
DRUG: Mitazalimab

Sponsor

University of Pennsylvania

Collaborators

[object Object]